China Slashes GLP-1 prices by as much as 80% due to rising rates of obesity
A fierce price war is reshaping China’s weight-loss market as companies slash costs by up to 80 percent to capture their share of a rapidly expanding sector. The competition intensified following the 2024 approval of obesity treatments from global leaders Novo Nordisk and Eli Lilly, with both foreign and domestic manufacturers now racing to establish … Read more